Athenex Provides Third Quarter 2021 Corporate and Financial Update
ET
- ET
BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the third quarter ended September 30, 2021. - Presented positive interim data from a Phase1 trial evaluating Oral Paclitaxel in combination with pembrolizumab in patients with advanced solid malignancies at ESMO 2021.
- In terms of product sales guidance, the Company is limiting financial guidance to the existing Athenex product portfolio only.
- Athenex will host a conference call and live audio webcast today, Thursday, November 4, 2021, at 10:00 am Eastern Time to discuss the financial results and provide a business update.